Thursday, March 23, 2017 10:46:46 AM
...
Cancer
Cancer has been the gateway to the medical marijuana industry. Multiple studies over the years showed marijuana helped reduce pain, anxiety, and increase appetite in cancer patients. Additionally, it doesn’t have the addictive quality of the opiates that are commonly given to cancer patients which often decrease appetite. Once again GW did a placebo study on a group with aggressive brain tumors using THC & CBD one half, and a placebo on the other. The results yielded 83% of a one yer minimum survival time in the group that received the THC/CBD and only 53% in the placebo group. Another company starting to experiment with brain cancer and cannabis is Pharmacyte Biotechnology, utilizing their patented Cell-in-a-Box technology. Essentially they use live cell encapsulationto deliver the concentrated amounts of THC & CBD to the location of the brain tumor, the capsules these cells are in protect them from escaping into the system before they reach their destination and from the body’s immune system. They also plan on using this technology for Type I & II Diabetes. It’s really interesting stuff, to learn more you can go here: http://pharmacyte.com/live-cell-encapsulation/
Live Cell Encapsulation Technology
http://pharmacyte.com/live-cell-encapsulation/
The Cell-in-a-Box® live cell encapsulation technology employed by PharmaCyte is a “platform” upon which treatments for different diseases may be built. This technology encloses live cells in protective “capsules” about the size of the head of a pin. The capsules are designed to allow blood to enter and nourish the living cells inside them. The live cells thrive while the capsules are in the body. But the capsules are also designed to protect the live cells from attack by the body’s immune system. The live cells are too large to escape from the capsules, and the body’s immune system cells are too large to enter the capsules and destroy them. PharmaCyte is using this technology to develop unique therapies for various forms of cancer and for Type 1 diabetes and insulin dependent Type 2 diabetes.
The encapsulation of living cells using the Cell-in-a-Box® technology is a multi-step process. To be encapsulated, the live cells are first suspended in a medium that contains a proprietary polymer and sodium cellulose sulfate. This suspension is passed through a droplet-forming machine, and the resulting droplets fall into a solution containing another polymer. As the two polymers interact, immediately a membrane forms around each droplet. This develops into a shell around the droplet, resulting in a spherical capsule 0.7-0.8 mm in diameter. For pancreatic cancer, each capsule contains about 10,000 living cells. This number of live cells can differ depending upon the size of the cells encapsulated and for what purpose they are to be used.
The capsules produced using the Cell-in-a-Box® encapsulation differ from those produced by others. Our competitors use substances such as alginate (a seaweed derivative) or chitosan, whereas our capsules are made principally of cellulose – a bio-inert material in the human body. The capsules durable, resilient and long-lasting. They can also withstand various external forces unlike those made using other encapsulation methods. The properties of our capsules allows them to be implanted in the human body by using needles or catheters without damage to the human body. Our capsules do not degrade, even after being present in the body for over two years. They do not cause any damage to or inflammation of tissues where they are located in the body.
Cells encapsulated using the Cell-in-a-Box® technology can be stored frozen at -80°C or lower for long periods of time and then successfully thawed – a necessity for shipment to distant locations. Large-scale manufacturing of encapsulated cells using this technology has been carried out according to current Good Manufacturing Practice (cGMP) conditions – a necessity for ultimately attaining marketing approval from drug regulatory authorities.
PharmaCyte has acquired the worldwide exclusive rights to this live-cell encapsulation technology for the development of treatments for all types of cancer using a certain type of cell line, for the treatment of diabetes and for the treatment of diseases and their symptoms using constituents from the Cannabis plant. The rights to use the cancer prodrug-activating cells that will be part of PharmaCyte’s therapies for advanced pancreatic cancer and breast cancer were also acquired.
The Cell-in-a-Box® Live Cell Encapsulation Facility
PharmaCyte’s partner, Austrianova, has constructed and equipped a cGMP-compliant facility in the Thai Science Park in Bangkok, Thailand. The facility will be used to encapsulate the live cells using the Cell-in-a-Box® technology. We will use the encapsulated live cells for our clinical trials discussed in other sections of this website.
Recent PMCB News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/13/2024 08:37:40 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/29/2024 08:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:59:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM